Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bukwang Pharmaceutical Co., Ltd. (003000.KS)
Seoul, KR
Bukwang Pharmaceutical Co., Ltd., a South Korean-based enterprise, conducts pharmaceutical operations both domestically and across international markets. The company manufactures a diverse array of pharmaceutical formats, encompassing oral solids, injectables, liquid solutions, and topical preparations like external-use solutions and ointments. Its product portfolio spans key therapeutic domains such as hepatology, featuring treatments like Levovir and Legalon for liver conditions; products addressing diabetic complications, including Dexid and Thioctacid; central nervous system disorder medications like Lonasen, Ixel, and Orfil; and respiratory disease remedies such as Azeptin and Asima. In addition to its prescription drug offerings, Bukwang provides over-the-counter (OTC) products, personal care items like toothpastes, hair, and skin care goods, and various nutritional supplements. Its comprehensive lineup extends to numerous other therapeutic categories, covering antihistamines, gastrointestinal disorders, oncology, endocrine conditions (thyroid, diabetes, osteoporosis), obstetrics, urogenital health, cardiovascular care, dermatology, weight management, and pain relief. It also addresses a wide spectrum of common ailments, including respiratory symptoms (colds, coughs, asthma), inflammatory and pain conditions (rheumatoid arthritis, osteoarthritis, general pain), various skin issues (infections, irritations), digestive complaints, and nutritional needs, along with specialized remedies for conditions like varicose veins and lactation support. Furthermore, the company supplies quasi-drugs, medical devices, and health functional foods. Committed to innovation, Bukwang is deeply involved in developing new treatments. This includes an anti-diabetes compound in collaboration with Melior Pharmaceuticals, anti-cancer drugs with LSK BioPartners, and explorations into adult stem cell-based therapies. It also possesses a licensing agreement for a promising candidate drug targeting movement disorders in Parkinson's disease patients. Established in Seoul, South Korea, in 1960, Bukwang Pharmaceutical remains strategically headquartered there.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.86% | -8.57% | -26.22% | -13.46% | +20.92% | +26.76% | +21.78% | -37.35% | -77.04% | -69.16% | +5.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+25.4% ★ Q1'26: -0.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+430.2% ★ Q1'26: +1,300.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.0% Q1'26: -10.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.1% Q1'26: +2.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.9% ★ Q1'26: +1.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+44.1% Q1'26: +42.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.09× ★ Q1'26: 7.18× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
142.13B
est: 150.00B (-5.2%)
|
138.62B
est: 153.00B (-9.4%)
|
150.74B
est: 163.00B (-7.5%)
|
194.22B
est: 194.20B (+0.0%)
|
168.19B
est: 166.40B (+1.1%)
|
169.66B
est: 173.60B (-2.3%)
|
182.49B
est: 184.50B (-1.1%)
|
190.91B
est: 183.00B (+4.3%)
|
125.93B
est: 208.00B (-39.5%)
|
160.09B
est: 160.09B (+0.0%)
|
200.71B
est: 200.71B (+0.0%)
|
| EBITDA |
28.41B
est: -2.89B (+1,081.9%)
|
26.73B
est: -2.95B (+1,005.6%)
|
20.98B
est: -3.14B (+767.3%)
|
197.93B
est: -3.75B (+5,383.1%)
|
5.35B
est: -3.21B (+266.7%)
|
2.21B
est: -3.35B (+166.0%)
|
11.40B
est: -3.56B (+420.3%)
|
4.89B
est: -3.53B (+238.4%)
|
-31.47B
est: -4.01B (-684.2%)
|
7.63B
est: -3.09B (+346.9%)
|
19.65B
est: -653.99M (+3,105.0%)
|
| EBIT |
23.29B
est: -7.37B (+415.8%)
|
21.03B
est: -7.52B (+379.6%)
|
14.88B
est: -8.01B (+285.7%)
|
191.06B
est: -9.55B (+2,101.0%)
|
-487.01M
est: -8.18B (+94.0%)
|
-3.95B
est: -8.54B (+53.8%)
|
6.56B
est: -9.07B (+172.3%)
|
-230.64M
est: -9.00B (+97.4%)
|
-35.76B
est: -10.23B (-249.7%)
|
3.52B
est: -7.87B (+144.7%)
|
14.16B
est: -6.29B (+325.1%)
|
| Net Income |
25.14B
est: 20.25B (+24.1%)
|
15.81B
est: 16.11B (-1.9%)
|
11.09B
est: 15.48B (-28.3%)
|
145.67B
est: 129.84B (+12.2%)
|
-7.43B
est: -3.05B (-144.0%)
|
-7.20B
est: 6.06B (-218.9%)
|
-916.62M
est: 7.09B (-112.9%)
|
-2.47B
|
-31.33B
est: 5.40B (-680.0%)
|
-2.64B
est: 6.81B (-138.8%)
|
12.57B
est: 12.36B (+1.8%)
|
| SGA |
14.82B
est: 16.45B (-9.9%)
|
18.72B
est: 16.78B (+11.6%)
|
16.50B
est: 17.88B (-7.7%)
|
20.13B
est: 21.30B (-5.5%)
|
22.24B
est: 18.25B (+21.8%)
|
15.26B
est: 19.04B (-19.8%)
|
13.49B
est: 20.24B (-33.3%)
|
19.82B
est: 20.07B (-1.3%)
|
22.11B
est: 22.82B (-3.1%)
|
16.84B
est: 17.56B (-4.1%)
|
24.81B
est: 23.37B (+6.2%)
|
| EPS |
425.03
est: 295.85 (+43.7%)
|
244.72
est: 235.34 (+4.0%)
|
161.59
est: 226.07 (-28.5%)
|
2,004.74
est: 1,896.76 (+5.7%)
|
-103.95
est: -44.52 (-133.5%)
|
-105.00
est: 88.48 (-218.7%)
|
-13.39
est: 103.50 (-112.9%)
|
-36.15
|
-458.00
est: 78.91 (-680.4%)
|
-38.59
est: 99.50 (-138.8%)
|
127.43
est: 125.23 (+1.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.01% | 72.7K | 0.15% |
| 2 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 429.2K | 0.06% |
| 3 | Kodex Inno-Tech Active 364690.KS | 0.01% | 1.1K | 0.30% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 822.9K | 0.06% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 21.9K | 0.44% |
| 6 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 35.3K | 0.24% |
| 7 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 35.3K | 0.24% |
| 8 | Vanguard FTSE Pacific ETF VPL | 0.00% | 260.2K | 0.07% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 170.4K | 0.39% |
| 10 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 4.0K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jae-Young Lee | Chief Executive Officer | — | male |
| Kyung-Min Kim | Director of CNS Division | — | — |
| Sang-Hoon Kim | Senior Managing Director, Head of Planning Adjustment Department and Representative Director | — | male |
| Sung-Gu Lee | President & Director | — | — |
| Tae-Hyun Kim | Vice President | — | — |
| Won-Tae Park | Managing Director and Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 003000.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
